Patents Assigned to THE USA AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES
-
Patent number: 10507235Abstract: One embodiment of the invention relates to a method to treat chordoma in an individual who has chordoma. The method includes the step of administering to an individual who has chordoma, an immunotherapeutic composition comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. Another embodiment of the invention relates to the use of an immunotherapeutic composition comprising a yeast vehicle and a cancer antigen comprising at least one Brachyury antigen to chordoma in an individual who has chordoma. Yet another embodiment of the invention relates to the use an immunotherapeutic composition comprising a yeast vehicle.Type: GrantFiled: March 19, 2014Date of Patent: December 17, 2019Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Timothy C. Rodell, David Apelian, Claudia Palena, Jeffrey Schlom
-
Patent number: 10407665Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.Type: GrantFiled: April 9, 2013Date of Patent: September 10, 2019Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
-
Patent number: 10383924Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.Type: GrantFiled: April 16, 2010Date of Patent: August 20, 2019Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
-
Publication number: 20190127695Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: ApplicationFiled: January 7, 2019Publication date: May 2, 2019Applicant: The Government of the USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Publication number: 20190119654Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: ApplicationFiled: October 29, 2018Publication date: April 25, 2019Applicant: The Government of the USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
-
Publication number: 20190002513Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.Type: ApplicationFiled: July 13, 2018Publication date: January 3, 2019Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang
-
Publication number: 20180346968Abstract: Methods for detecting presence of one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis nucleic acids in a sample, such as a biological sample obtained from a subject, or an environmental sample, are provided. This disclosure also provides probes, primers, and kits for detecting one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis in a sample.Type: ApplicationFiled: August 6, 2018Publication date: December 6, 2018Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Bernard Wolff, Jonas M. Winchell, Maureen Diaz
-
Publication number: 20180327870Abstract: Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.Type: ApplicationFiled: July 23, 2018Publication date: November 15, 2018Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Stephen Lindstrom, Lamorris Loftin
-
Publication number: 20180264098Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.Type: ApplicationFiled: May 31, 2018Publication date: September 20, 2018Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health and Human ServiceInventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
-
Publication number: 20180112178Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: ApplicationFiled: November 22, 2017Publication date: April 26, 2018Applicant: The Government of the USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Publication number: 20160289748Abstract: Methods for detecting Legionella (such as Legionella spp., Legionella pneumophila, Legionella pneumophila serogroup 1, Legionella bozemanii, Legionella dumoffii, Legionella feeleii, Legionella longbeachae, and/or Legionella micdadei) are disclosed. A sample suspected of containing one or more Legionella nucleic acids is screened for the presence or absence of that nucleic acid. Determining whether Legionella nucleic acid is present in the sample can be accomplished by contacting the sample with detectably labeled probes capable of hybridizing to a Legionella nucleic acid and detecting hybridization between the probes and nucleic acids in the sample. Detection of hybridization indicates that a Legionella nucleic acid is present in the sample. Also disclosed are probes and primers for the detection of Legionella, and kits that contain the disclosed probes and/or primers.Type: ApplicationFiled: June 20, 2016Publication date: October 6, 2016Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health and Human ServiceInventors: Jonas M. Winchell, Alvaro J. Benitez
-
Publication number: 20150359853Abstract: In one aspect, described herein are cyclical administration regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15Ra”) to patients in order to enhance IL-15-mediated immune function. In one aspect, these cyclical administration regimens achieve plasma levels of IL-15 above basal levels while minimizing the toxicity associated with IL-15 administration. In a specific aspect, the cyclical administration regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. Also described herein are purified soluble forms of IL-15Ra, cells that recombinantly express soluble forms of IL-15Ra, and compositions comprising complexes of IL-15 covalently or non-covalently bound to soluble forms of IL-15Ra.Type: ApplicationFiled: October 23, 2013Publication date: December 17, 2015Applicants: ADMUNE THERAPEUTICS LLC, THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John N. Vournakis
-
Publication number: 20150299246Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: ApplicationFiled: April 28, 2015Publication date: October 22, 2015Applicants: Purdue Research Foundation, THE GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICESInventors: Mark S. CUSHMAN, Yves George POMMIER, Peng-Cheng LU, Christophe MARCHAND, Keli AGAMA
-
Publication number: 20150246951Abstract: Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glycoprotein cross-reactive epitopes and flavivirus E-glycoprotein cross-reactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection.Type: ApplicationFiled: March 16, 2015Publication date: September 3, 2015Applicant: The Government of the USA as represented by the Secretary of the Dept.of Health and Human ServicesInventors: Gwong-Jen J. Chang, Wayne D. Crill
-
Publication number: 20150038419Abstract: The present invention includes a novel protein, also referred to herein as simukunin, that inhibits the function of several physiologically important enzymes. Simukunin is a potent inhibitor of the blood coagulation cascade, inhibiting Factor Xa and functioning as an efficient anticoagulant. Simukunin also inhibits the serine proteases elastase and cathepsin and demonstrates anti-inflammatory properties. Also included are methods of making and using simukunin.Type: ApplicationFiled: May 25, 2012Publication date: February 5, 2015Applicants: THE GOVERNMENT OF USA, as represented by the Secretary of the Dept. of Health & Human Services, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: Donald E. Champagne, Hitoshi Tsujimoto, Ivo Francischetti, Michael R. Strand, Michail Kotsyfakis
-
Publication number: 20140187525Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: ApplicationFiled: March 7, 2014Publication date: July 3, 2014Applicants: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, LABORATOIRE HRA-PHARMAInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Publication number: 20140088175Abstract: The present invention provides methods of transcytosing barrier epithelial cells using adeno-associated virus-4 (AAV4), adeno-associated virus-5 (AAV5), adeno-associated virus-7 (AAV7), bovine adeno-associated virus (BAAV), and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid across the barrier epithelia using the AAV4, AAV5, AAV7, and BAAV vectors and particles.Type: ApplicationFiled: March 9, 2012Publication date: March 27, 2014Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: John A. Chiorini, Giovanni Di Pasquale
-
Publication number: 20140065603Abstract: A method is provided for reverse transcription-polymerase chain reaction (RT-PCR) comprising a) amplifying a reverse transcribed cDNA in a mixture comprising Norovirus Genogroup I and Norovirus Genogroup II primers and probes, wherein said Norovirus primers and probes distinguish between Genogroup I and Genogroup II viruses; b) quantifying virus; and c) normalizing data based on a universal internal RNA control. Optionally, the method may also include primers and probes for Enteroviruses. A reaction mixture comprising Norovirus Genogroup I and Norovirus Genogroup II primers and probes, wherein said Norovirus primers and probes distinguish between Genogroup I and Genogroup II viruses and universal internal RNA control primers and probes are also included.Type: ApplicationFiled: September 30, 2013Publication date: March 6, 2014Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: William Burkhardt, III, Michael C.L. Vickery, Jessica Nordstrom
-
Publication number: 20130230456Abstract: Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP)Type: ApplicationFiled: February 8, 2013Publication date: September 5, 2013Applicant: The USA as represented by the Secretary, Dept. of Health and Human Services; National Institutes ofInventor: The USA as represented by the Secretary, Dept. of Health and Human Services; National Institute of Health
-
Publication number: 20130217861Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: ApplicationFiled: November 30, 2010Publication date: August 22, 2013Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: David M. Neville, JR., Jung-Hee Woo, Yuan-Yi Liu